Cambridge, Mass.-based Akcea Therapeutics priced its offering of 15.6 million shares at $8 apiece to reach its $125 million IPO target. The company initially priced an offering of 9.6 million shares at $12 to $14 per share.
Akcea’s shares are slated to begin trading on the Nasdaq exchange today under the “AKCA.”
The biotech is a subsidiary of Ionis Pharmaceuticals (NSDQ:IONS) and is developing an injectable drug, volanesorsen, to treat rare lipid disorders that present with high levels of trigycerides and pancreatitis.
The company has conducted two late-stage trials of its drug as a therapy for patients with familial chylomicronemia syndrome. It is also running a Phase III trial for patients with familial partial lypodystrophy.
Akcea reported that the proceeds from its IPO will help commercialize volanesorsen and support more clinical trials.
In January, Novartis inked a collaborative deal with Akcea, forking over $75 million up front for the right to license and develop two drugs as potential therapies for cardiovascular disease.
Novartis also agreed to buy up $50 million in Akcea stock at the price set for its IPO.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.